WallStSmart

Krystal Biotech Inc (KRYS)vsRevolution Medicines Inc (RVMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Krystal Biotech Inc generates 56140% more annual revenue ($417.30M vs $742,000). KRYS leads profitability with a 53.9% profit margin vs 0.0%. KRYS earns a higher WallStSmart Score of 65/100 (C+).

KRYS

Buy

65

out of 100

Grade: C+

Growth: 8.3Profit: 9.0Value: 4.7Quality: 9.0
Piotroski: 4/9Altman Z: 7.95

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 7.3
Piotroski: 2/9Altman Z: 3.27

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

KRYS6 strengths · Avg: 10.0/10
Profit MarginProfitability
53.9%10/10

Keeps 54 of every $100 in revenue as profit

Operating MarginProfitability
46.1%10/10

Strong operational efficiency at 46.1%

Revenue GrowthGrowth
31.9%10/10

Revenue surging 31.9% year-over-year

EPS GrowthGrowth
52.5%10/10

Earnings expanding 52.5% YoY

Debt/EquityHealth
0.0110/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
7.9510/10

Safe zone — low bankruptcy risk

RVMD1 strengths · Avg: 10.0/10
Altman Z-ScoreHealth
3.2710/10

Safe zone — low bankruptcy risk

Areas to Watch

KRYS1 concerns · Avg: 4.0/10
P/E RatioValuation
39.7x4/10

Premium valuation, high expectations priced in

RVMD4 concerns · Avg: 3.5/10
Price/BookValuation
17.1x4/10

Trading at 17.1x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Comparative Analysis Report

WallStSmart Research

Bull Case : KRYS

The strongest argument for KRYS centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 53.9% and operating margin at 46.1%. Revenue growth of 31.9% demonstrates continued momentum.

Bull Case : RVMD

The strongest argument for RVMD centers on Altman Z-Score.

Bear Case : KRYS

The primary concerns for KRYS are P/E Ratio.

Bear Case : RVMD

The primary concerns for RVMD are Price/Book, EPS Growth, Profit Margin.

Key Dynamics to Monitor

KRYS profiles as a growth stock while RVMD is a value play — different risk/reward profiles.

RVMD carries more volatility with a beta of 1.41 — expect wider price swings.

KRYS is growing revenue faster at 31.9% — sustainability is the question.

KRYS generates stronger free cash flow (73M), providing more financial flexibility.

Bottom Line

KRYS scores higher overall (65/100 vs 24/100), backed by strong 53.9% margins and 31.9% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Krystal Biotech Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Krystal Biotech, Inc., a clinical-stage biotechnology company, is dedicated to the field of redosable gene therapy to treat serious rare diseases in the United States. The company is headquartered in Pittsburgh, Pennsylvania.

Visit Website →

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?